>
State of Play is a read on a sector: its size, its structure, where the money moves and what moves it. Each edition takes one market and sets out what is known, what is claimed, and what the difference between the two is worth to anyone deciding where to commit.
A rich payer, bottomless sovereign capital, state-built platforms and top-down mandates: the Gulf has every ingredient digital health needs, except the one it cannot buy. The Gulf’s digital-health market read in full: the payer and the platforms that make it the envy of the emerging world, and the scale it cannot reach.
Figures carry their basis and their date. Where published estimates disagree, the range is given and the basis named rather than averaged away, and where a widely quoted number does not survive checking it is corrected here rather than repeated. Every chart plots a figure stated in the text, and nothing is projected beyond what a named source projects.
One inversion drives everything that follows: the Gulf has solved the problems that gate digital health everywhere else, and is left with the one problem money cannot solve.
In most of the world, digital health is throttled by two things: no payer willing to fund it, and no capital to build it. The Gulf has solved both. It has a rich institutional payer, universal state care plus mandatory insurance, with telehealth reimbursed at the same rate as an in-person visit. It has bottomless sovereign capital and some of the largest AI compute on the planet. Its government-built platforms are among the best anywhere, from the biggest virtual hospital on earth to national health-record exchanges. Demand is acute, driven by one of the heaviest disease burdens anywhere. The Gulf has every ingredient digital health needs, except scale.
That one missing ingredient decides the rest, because it is the only one sovereign capital cannot buy. The entire six-state Gulf holds about 61.2 million people, a fifth of the United States, a twenty-third of India, split across six separately-regulated markets with incompatible data regimes, and dominated by a transient, expatriate-heavy population. Three consequences run off that arithmetic.
The Gulf is thus the best-resourced digital-health market in the emerging world and the hardest place in it to scale a private company. Value goes to whoever builds for the sovereign and the AI layer, not to anyone chasing consumer scale the population cannot supply.
The inversion holds, though the basis on which it was first argued has moved. The movement sharpens the conclusion. Market Research Future re-cut its GCC digital-health series in 2026, from about US$5.41 billion compounding at roughly 21 per cent a year to about US$6.28 billion in 2025 (Market Research Future, 2026). The revised series rises to about US$23.8 billion by 2035 at about 14.2 per cent. The level is higher and the compounding is slower, so the terminal market implied for 2035 is smaller than the earlier basis suggested. Growth above 20 per cent survives only at country level, where Saudi Arabia is put at about 22 per cent to 2032 and the UAE at about 23 per cent to 2035. A region compounding at 14
per cent rather than 21 per cent has less room to grow out of its scale constraint, not more.
The platform evidence has moved too. Seha Virtual Hospital, relaunched in March 2025, connects 241 hospitals and more than 1,400 health centres (Saudi Ministry of Health, 9 August 2026). That is a wider footprint than the hospital count alone conveys, and a correction to the 242-hospital figure carried earlier in this series. Above it sit the citizen front-ends, Sehhaty, Mawid and the 937 service, and in the UAE three interconnected exchanges through which roughly 1.9 billion records are accessible (Malaffi, NABIDH and Riayati, 2026).
The payer is arriving unevenly. Compulsory cover took effect in the UAE on 1 January 2025 and Saudi Arabia requires Council of Health
Insurance-compliant cover from every private employer, but Bahrain's SEHATI and Oman's Dhamani are still phasing in rather than fully in force. The payer advantage is real in two markets and prospective in the others, the same two-market concentration the scale argument describes.
The Gulf is the mirror image of every other emerging digital-health market, and its problem is the exact opposite one.
The Gulf inverts the usual emerging-market story. Elsewhere, in India, across Africa, the constraint sits on the demand side. Patients pay out of pocket and no payer funds the care. Capital is scarce, and the unit economics never work no matter how vast the population. The Gulf has the opposite profile. Its demand side is the strongest in the world. A state-and-insurer payer funds digital care, sovereign capital is in near-limitless supply, and government platforms are built top-down at national scale. By every measure that throttles digital health elsewhere, the Gulf is rich.
And yet it has its own, opposite constraint. What the Gulf lacks is not money or a payer but people, or, more exactly, scale. The whole region is a market of 61.2 million, smaller than many single countries, and it is not even one market but six, each with its own regulator, data regime and rules. The very thing that makes a consumer health-tech company valuable, the ability to win tens of millions of users cheaply and grow into a vast addressable market, is precisely what the Gulf cannot offer. The region has every advantage but one, and the one it lacks governs the use it can make of the rest.
Three structural models frame the inversion, not two. The United States runs a payer-led market. Its binding constraint is cost. India runs public
rails without a dominant payer, so its constraint is unit economics. The Gulf runs a payer-by-mandate alongside a state-built platform, and its constraint is scale and fragmentation (Volge analysis, 2026). The Gulf's difficulty is therefore not a weaker version of the Indian problem but a different problem. It is the only one of the three that legislation, reimbursement design and capital deployment cannot address.
The demand side can be measured. Gross domestic product per head across the six states runs between about US$23,000 and US$81,000, with near-universal smartphone use. Adoption, where it has been studied, is high. Retention across digital-health app categories in Saudi Arabia and the UAE has been put at 64 to 87 per cent, with e-pharmacy the
most-used solution in both markets (McKinsey, cited 2026). A population that is wealthy, connected and willing to use the services is the precondition most emerging markets lack.
What is lacking is aggregation, and the count of borders is higher than the count of states. The six markets are governed by seven health regulators and three separate health-data regimes, so a regional platform must license, integrate and comply several times over before it reaches the users any single market can supply. The arithmetic is therefore strong demand, a solved payer, abundant capital, and a market that must be assembled state by state rather than entered once.
The Gulf digital-health market is real and growing fast, provided it is not mistaken for the much larger region around it.
Anchor the Gulf digital-health market at about $6.3 billion in 2025, on its way to roughly $24 billion by 2035 at about 14% a year, with telemedicine a smaller slice near $530 million and e-health around $2.7 billion. Healthy growth, underwritten by the build-out and the payer. But the single most important discipline in sizing this market is geographic: the GCC is not the Middle East, and not the wider MEA region.
The distinction matters because the bigger labels produce bigger numbers that get routinely mislabelled. The “Middle East” digital-health market is put near $14 billion in 2025, and MEA higher still. Those figures fold in Egypt, Iran, Africa and more. They must never pass for Gulf. Within the GCC itself, Saudi Arabia and the UAE dominate, together some 83% of regional health spending. The honest framing is a modest but fast-growing market, around $6 billion today. Its apparent size is often inflated by regional confusion, and its real ceiling is set not by growth rates but by the population behind the numbers.
The sizing basis used here is itself a correction. The series on which this read's central argument was built, roughly US$5.41 billion compounding at about 21 per cent a year, has been superseded. Market Research Future re-cut the same GCC series in 2026 to about US$5.5 billion in 2024 and about US$6.28 billion in 2025, reaching about US$23.8 billion by 2035 at about 14.2 per cent. The consequence for the argument is real. Compounding at 14 per cent rather than 21 per cent, the region reaches a smaller market in 2035 than previously projected. The claim that Gulf digital health compounds above 20 per cent now holds only for Saudi Arabia, at about 22 per cent to 2032, and the UAE, at about 23 per cent to 2035.
Beneath the headline the segment series diverge, and they must not be added together. GCC e-health is put at about US$2.7 billion in 2024, rising to about US$10.0 billion by 2033 at about 15.6 per cent. E-pharmacy is put at about US$2.37 billion in 2024, rising to about US$9.44 billion by 2033 at
about 15.4 per cent. Telehealth, the fastest slice, runs from about US$0.44 billion in 2024 to about US$2.6 billion by 2033 at about 21.9 per cent (IMARC and Precedence Research, 2024 to 2026). The scopes overlap substantially. A reader who sums them will double-count.
The honest position is a range, not a point, and a scope stated rather than implied. Published GCC estimates for 2025 sit between about US$5.5 billion and US$6.3 billion, and the growth rate sits between about 14 and 22 per cent, depending on whether the whole region or only its two leading markets is being measured.
That advantage runs straight into digital health, because the payer pays for virtual care. Dubai reimburses a telemedicine consultation at the same rate as an in-person one, and Abu Dhabi pays a flat fee per visit. Saudi Arabia builds telehealth into its public system. The contrast with India is the whole thesis in a single fact. Indian digital-health companies cannot get anyone to pay for the outpatient consultation they sell, whereas Gulf telehealth is reimbursed by insurers and the state at parity. The
unit-economics ceiling that crushes digital health elsewhere simply does not exist here. The payer problem is solved. That makes the scale problem which remains all the more striking.
The Gulf has the one thing Indian digital health would trade almost anything for: somebody other than the patient who pays.
The Gulf’s defining advantage, and its sharpest contrast with other emerging markets, is its payer. Across all six states, the government funds universal care for citizens, and mandatory employer-paid insurance covers the large resident population; from January 2025 the UAE completed its rollout, so every emirate now enforces compulsory cover. Out-of-pocket spending sits in the low teens as a share of health expenditure, around 16% in Saudi Arabia, 13% in the UAE, single digits in Oman, against 50 to 60% in India. The patient is not the payer.
Gulf states are legislating the payer into existence, and at different speeds. Saudi Arabia requires Council of Health Insurance-compliant cover from every private employer. The kingdom's mandate is therefore already operative, and not, as earlier drafts of this series implied, awaiting a 2026 programme. Bahrain's SEHATI was established under Law 23 of 2018 and carries an allocation of BD 688 million against roughly 686,000 expatriate residents and their dependants. Oman's Dhamani launched its platform on 1 January 2025. Both are still phasing in. Neither is yet fully in force (national health authorities, 2026). The payer advantage is therefore complete in two markets and partial in the remaining four.
The advantage monetises through the claim, not the consultation, and the claims rail is being enforced. Dubai's eClaimLink, reinforced by directive PD-05-2025, requires electronic claims submission under defined timelines with penalties for failure, which makes integration with the claims layer a condition of being paid rather than an optimisation. Premium
growth confirms the widening pool: UAE health premiums rose about 12.7 per cent in the first half of 2025.
Value is accruing accordingly. Health insurtech and claims is the strongest segment in Gulf digital health, precisely because the mandate created the counterparty. Klaim, a provider claims-fintech, raised a US$26 million Series A in 2025. Sehteq, an artificial-intelligence-led health insurer, reports more than 700,000 customers (company disclosures, 2025 to 2026). The lesson for an entrant is that the payer is reached through the claim, the employer and the insurer, not through the patient.
Behind the payer sits a population that needs digital health: sick, and short of the clinicians to treat it.
The demand for digital health in the Gulf is not manufactured by policy. It comes from a real and acute clinical need. The region carries one of the heaviest chronic-disease burdens in the world, diabetes prevalence among the highest anywhere, Saudi Arabia at 23.1% of adults, Kuwait at 25.6%, and non-communicable diseases behind the large majority of all deaths. That burden demands exactly what digital health supplies. Chronic-disease management and remote monitoring are wanted, as are regular teleconsultation and AI-assisted screening.
Compounding the need is a shortage of clinicians. The Gulf runs below developed-world physician and nurse densities, and its health workforce is overwhelmingly expatriate, in the UAE, an estimated 82% of physicians and 96% of nurses; in Saudi Arabia, around 90% of private-sector health staff. A population this sick, served by a workforce this stretched and this mobile, is the strongest possible case for digital health. Telemedicine stretches scarce doctors across distance, and remote monitoring manages chronic disease without a clinic visit. AI multiplies clinical capacity. The demand side is as compelling as the payer side. The Gulf needs digital health, can pay for it, and is building it, which is what makes the scale constraint so central.
Diabetes prevalence across the Gulf now runs from 18.7 to 25.6 per cent of adults against a global 11.1 per cent, on the International Diabetes Federation's 11th edition, published in 2025 on 2024 estimates. That supersedes the 9th-edition figures on which earlier Gulf reads were built, where the range was roughly 15 to 22 per cent. The re-base also re-orders the region. Qatar, at 24.6 per cent, now ranks second, ahead of Saudi Arabia. Bahrain is at 22.1 per cent and the UAE at 20.7 per cent, with Oman, re-based most steeply of all, at 18.7 per cent.
The burden is therefore heavier, and more evenly distributed, than the earlier figures suggested. No Gulf state now sits below about 19 per cent, which means chronic-disease demand is a regional condition rather than a Kuwaiti and Saudi one, and it falls on health systems whose clinical workforce is largely imported and contested.
The demand pulls two things specifically. Remote monitoring and chronic-care management is the fastest-growing edge of Gulf digital health, drawn directly by the diabetes burden, and it is the segment where continuous engagement is now monetisable because the arriving payer reimburses it. Clinical artificial intelligence is the second draw, for the same reason in reverse. The constraint it relieves is a shortage of clinicians, not a shortage of patients. The demand side of this market does not need to be created, only served and billed. The second part is the decisive one.
Scale matters because consumer health-tech economics depend on it. The venture model runs on winning users cheaply and growing into a vast market, spreading the high fixed costs of technology and regulation across tens or hundreds of millions of them. In the Gulf the user numbers
are capped by demography, so the fixed costs cannot be amortised the same way, and the returns that justify venture capital are harder to reach. The population compounds the problem: it is heavily expatriate and transient, nearly 90% of the UAE and Qatar are non-nationals, many of whom leave, which makes the user base small and unstable. The Gulf can fund and build digital health superbly. What it cannot do is provide the scale that makes a private digital-health company valuable.
Every advantage the Gulf has runs into one wall: there are not enough people, and they are not in one market.
Scale is the constraint that defines this market, and the numbers are stark. The whole six-state Gulf holds about 61.2 million people, roughly a fifth of the United States, a twenty-third of India. Saudi Arabia, at 35.3 million, is the only large national market, and the UAE has about 11.4 million. The other four are small. Oman and Kuwait hold around 5 million each, Qatar 3.2 million and Bahrain 1.6 million. For a digital-health company this is a hard ceiling. The addressable population is a fraction of what a comparable business in India, the United States or Indonesia can reach.
The scale constraint can be read directly in the capital that reaches the sector, which is the market's own verdict on its size. Disclosed GCC
health-technology investment amounted to about US$148 million across 32 startups between January 2025 and July 2026, comprising 21 rounds in 2025 and 11 in the first half of 2026. Saudi Arabia accounted for 17 of the companies and the UAE for 11 (PitchBook, via WHX Tech, 2026). In the same period MENA startups across all sectors raised about US$2.1 billion in the first half of 2025 alone, up about 134 per cent year on year. Capital is plentiful in the region. In this sector it is scarce. That is a statement about addressable scale rather than about appetite.
The regulatory arithmetic compounds the demographic arithmetic. The six markets carry seven health regulators and three separate health-data regimes, so the fixed cost of licensing, exchange integration and data residency is incurred repeatedly while the user base it unlocks is added in small
increments. A platform that would be built once for a single large market must here be built, certified and hosted several times for the same aggregate population.
Distribution follows from that structure. Direct-to-consumer in the Gulf is viable only for premium or specialty propositions, or for a platform already operating at regional scale, because acquisition cost is high and the domestic audience in any one state is small. Regional aggregation is not a growth ambition here but the minimum condition of viability.
The 61 million is not even one market. It is six, and the borders between them are real.
The scale problem is worse than the headcount alone suggests, because the 61.2 million is not a single market. It is six. Each is a sovereign state with its own health regulator and licensing regime. More decisively, each has its own data-protection and data-localisation rules. A digital-health company cannot build once and serve the region. It has to register, license and comply separately in Saudi Arabia, the UAE, Qatar, Kuwait, Oman and Bahrain. Within the UAE alone it faces three onshore health regulators and two further free-zone data regimes.
The fragmentation hits digital health in a specific, damaging way. Unlike physical goods, digital health runs on data, and the Gulf states require health data to stay within national borders. A single regional platform, sharing records and serving patients across the six markets, is therefore not legally straightforward. The natural scale economy that would let a Gulf company aggregate the region into one addressable market is blocked by the region’s own internal data borders. Even the modest 61 million is sliced into six smaller pools. They are not equal. Two of them (Saudi Arabia and the UAE) hold most of the value, and four are too small to anchor a business alone. Fragmentation, layered on small populations, is what turns a scale disadvantage into a scale wall.
Seven health regulators and three separate health-data regimes govern the six states. That is a higher count of borders than the headline six implies, and the figure that matters to anyone budgeting an entry. The additional regulator arises from the UAE's division of health authority between the federal ministry and the emirate-level authorities. Integration obligations follow the same division. A telemedicine platform must connect to NABIDH in Dubai, to Malaffi in Abu Dhabi and to Riayati nationally. The relevant exchange is determined by where the patient is treated rather than by where the company is domiciled.
The fragmentation is one of multiplicity rather than of legal uncertainty, and that distinction is to the Gulf's credit. Indian e-pharmacy, by contrast, has operated without a notified framework. The Gulf regimes are written,
in force and enforced. The Saudi Food and Drug Authority introduced mandatory licensing and prescription controls for online pharmacies in 2023, and telehealth is licensed nationally in each state under published practice rules. An entrant faces a known set of obligations repeated six or seven times, which is a more navigable problem than an unknown set repeated once.
The cost, however, is cumulative and permanent. Each regime requires its own licence, its own integration and, where data residency applies, its own hosting, so the compliance burden scales with the number of markets entered rather than with the number of patients served. It is the clearest reason why the winning Gulf model aggregates deliberately across the region from the outset rather than expanding into it opportunistically.
In the Gulf, the state does not just fund digital health or regulate it. It builds it, and that changes the whole market structure.
The defining structural feature of Gulf digital health is that the government is the payer, the regulator and the builder. In most markets private companies build the platforms, while the state at most pays or regulates. In the Gulf the state itself constructs the digital-health infrastructure at national scale, the virtual hospitals, the super-apps, the national electronic health records and exchanges. The same sovereign that funds the care also owns the platform delivering it.
This top-down model is the Gulf’s answer to the scale problem. It is a powerful one. A government does not need venture-scale user economics to justify a platform. It can deploy one nationally by mandate, fund it from sovereign budgets, and require facilities and citizens to use it. So the platforms that would, elsewhere, be built by venture-backed startups racing for scale are, in the Gulf, built by the state for the whole population at once. The most valuable digital-health assets in the Gulf are therefore government-owned, and the private startup layer is correspondingly thin. The strategic question for any commercial player is how to build with,
around or for the sovereign platforms rather than against them. That is a structural difference, not a difference of degree.
The Gulf state occupies four positions at once, and an entrant must know which one it is addressing. It is the regulator, the payer, the builder of the rails and, through the sovereign funds, the largest potential acquirer. Beneath that sit four buyer pools. Each has its own economics. The state buys for its public platforms, and the insurers buy because cover is now compulsory. Employers fund group cover for staff and dependants, and the hospital systems buy clinical software and analytics (Volge analysis, 2026). The out-of-pocket consumer, which dominates Indian digital health, is the weakest of the five in the Gulf.
The build itself is layered rather than monolithic. Saudi Arabia's Seha Virtual Hospital, relaunched in March 2025, supplies the clinical layer. The citizen front-ends, Sehhaty, Mawid and the 937 service, handle appointments, records and telemedicine for the population. In the UAE the health-information exchanges supply the data layer with which telemedicine platforms are required to integrate. Distribution and trust, the two most expensive
things a consumer health business must buy elsewhere, are therefore available in the Gulf as public infrastructure.
The dependency is the price of the advantage. It is a real one. Building on government rails means building at the state's pace, and the rails differ by country, so a platform's roadmap becomes partly a function of a ministry's. The standing mitigation is diversification of channel rather than of market. An operator that earns the insurer, the employer and the hospital alongside the state is less exposed to any single programme's timetable than one whose whole distribution runs through a public platform.
The clearest proof of the sovereign-platform model is, by a verified world record, the largest virtual hospital on earth.
Saudi Arabia’s Seha Virtual Hospital is the flagship of the sovereign-platform model and a genuine global first. Launched by the health ministry in 2022, it was certified by Guinness World Records in October 2024 as the largest virtual healthcare provider in the world. The record was audited. It is not a marketing line. By the ministry’s 2026 figures it connects more than 242 hospitals, spans dozens of specialties and sub-specialties, and carries an annual beneficiary capacity approaching 600,000.
In 2025 it delivered over 16 million virtual appointments and handled hundreds of thousands of complex clinical cases, growing hard year on year.
Seha shows exactly what the top-down model can do that a private company could not. No venture-backed startup, capped by the scale ceiling, could have built a virtual hospital for an entire nation. The Saudi state simply built it, funded it and deployed it across the kingdom by mandate. It hits the demand-side need squarely, stretching scarce specialists across distance to a sick, under-served population, at a scale the private market’s economics would never have justified. Seha is the answer to the scale problem from the only actor that can transcend it. That actor is the sovereign, building national digital-health infrastructure as a public good rather than a venture. It is a warning to private players. The most valuable telehealth platform in the kingdom belongs to the state.
Seha Virtual Hospital connects 241 hospitals and more than 1,400 health centres (Saudi Ministry of Health, 9 August 2026), which supersedes both the 242-hospital figure carried in this series and the 224 hospitals cited in earlier editions. The correction is not merely arithmetical. The hospital
count alone understates the platform. The primary-care layer of more than 1,400 health centres is where chronic-disease management at population scale actually reaches the patient. The hospital was also relaunched in March 2025 on an expanded service model. Both the reach and the primary-care layer beneath it are wider than the earlier figures implied.
The reported outcomes are what make the platform matter, not merely its size. Seha is credited with a reduction of about 40 per cent in hospital stays and about 25 per cent in readmissions, delivered through artificial-intelligence-assisted triage, remote consultation and specialist support across the kingdom (Saudi Ministry of Health, 2026). Those are the two measures a payer cares about, which is why the platform is treated here as health-system infrastructure rather than as a telemedicine service.
The competitive consequence for private operators is correspondingly narrow. Basic virtual consultation in Saudi Arabia is occupied by a free, well-funded public service with national reach, so a private platform cannot compete on price or on breadth. What remains available is specialty depth, insurer integration, convenience and demonstrated outcomes, and in many cases the better commercial position is to supply or integrate with the public platform rather than to contest it.
Beneath the apps, the Gulf has built national digital nervous systems, one per state, which is both the strength and the snare.
The deepest layer of Gulf digital health is the national electronic health record and health-information exchange. Here the sovereign-platform model is most fully realised, state by state. The UAE runs Riayati, a federal unified medical record linking over 3,000 facilities. Alongside it sit Abu Dhabi’s Malaffi (the region’s first health-information exchange, joining some 3,000 facilities and 50,000 clinicians) and Dubai’s Nabidh (over 10
million records and 53,000 professionals). Saudi Arabia runs its national exchange through the PIF-owned platform companies, and Qatar runs a national record on a global electronic-health-record system. Kuwait launched its consolidated “Salem” app in late 2025, unifying over 100 million records. Oman and Bahrain run national systems too.
| System | Market | Scale |
|---|---|---|
| Malaffi (HIE) | Abu Dhabi | First HIE in MENA; ~3,000 facilities, 50k clinicians |
| Nabidh (HIE) | Dubai | 10M+ records, 53k professionals |
| Riayati (EHR) | UAE federal | 3,000+ facilities connected |
| Salem (app) | Kuwait | 100M+ records unified (2025) |
These exchanges are genuine achievements, national digital nervous systems most countries lack, and they embody the read’s tension precisely. Each is built at the scale of one nation, by the state, for the whole population. That is the sovereign model working as designed. But each is also national, walled by data-localisation rules, and incompatible with its neighbours. The very infrastructure that gives each Gulf state a national-scale digital backbone simultaneously hardens the borders between the six markets. The records cannot cross them. The EHRs and HIEs are the clearest case of the Gulf doing digital health superbly within each state and, in the same stroke, making a unified regional market harder to build.
Two figures here need correction, and the corrected ones strengthen the chapter's point. Riayati connects about 5,000 facilities rather than the
3,000 stated, and NABIDH holds about 10.4 million records across 1,888 connected facilities; taken together, the UAE's three interconnected exchanges make roughly 1.9 billion records accessible (Malaffi, NABIDH and Riayati, 2026). Integration with the relevant exchange is not optional: telemedicine platforms are required to connect to NABIDH in Dubai, Malaffi in Abu Dhabi and Riayati nationally.
Beneath the exchanges the enterprise layer is concentrated in two foreign vendors. Oracle Health, formerly Cerner, is the dominant hospital electronic-medical-record system across Saudi Arabia, the UAE, Qatar and Oman, while Epic holds the premium tertiary sites including Cleveland Clinic Abu Dhabi and Sidra Medicine (vendor and provider disclosures,
2025 to 2026). The record layer on which Gulf digital health runs is therefore imported, and the exchanges that aggregate it are sovereign.
The opportunity this leaves an entrant is specific. The enterprise record is not contestable, but the integration layer above it is, as are the clinic and specialty applications beneath it and the analytics built on the pooled data. It is also the precondition for the region's artificial-intelligence ambitions: pooled records at national scale are what a clinical model requires, and the Gulf has them in a form most health systems do not. The same localisation that walls the records from each other is what made each national pool coherent enough to build on.
The Gulf’s most extravagant advantage is the one least relevant to scale and most relevant to AI: near-limitless capital and compute.
If scale is the Gulf’s scarcity, capital and compute are its abundance, and the figures dwarf anything in the private health-tech market. Abu Dhabi’s G42, whose health arm helped form M42, took a $1.5 billion investment from Microsoft in 2024. It also runs Condor Galaxy, among the most powerful AI supercomputer networks on earth, on which its medical AI was trained. Saudi Arabia’s HUMAIN, backed by the Public Investment Fund, struck partnerships in 2025 to deploy up to 600,000 advanced AI
chips with one vendor alone, alongside multi-billion-dollar deals with others. Healthcare was named an early priority. The UAE’s Stargate project is building a gigawatt-scale AI campus.
The contrast with private health-tech funding is the whole point. The Gulf spends billions on sovereign compute while its entire health-tech venture market raises tens of millions. Capital is not the constraint here. This is the mirror image of India, where capital is scarce and the population vast. So the Gulf’s advantage lies wherever capital and compute matter more than user scale, which is the AI layer. Sovereign compute cannot manufacture a large population, but it can train clinical AI to the highest standard, and that is where the Gulf pours its abundance. The advantage is extravagant, and aimed squarely at the one part of digital health where the number of users matters least.
Sovereign capital and venture capital in this sector differ by orders of magnitude, and the comparison is the one that matters. The Gulf's largest sovereign funds command roughly US$5 trillion in aggregate, and increasingly direct it at health technology as part of the diversification agenda. Saudi Arabia's Public Investment Fund anchors the build, and HUMAIN, its artificial-intelligence venture vehicle, is capitalised at about US$10 billion (sovereign-fund and company disclosures, 2025 to 2026). Disclosed GCC health-technology venture investment over the eighteen months to July 2026 was about US$148 million.
The funds do not merely invest, which is the distinction that matters to an operator. Mubadala and G42 created M42 to fuse care delivery with applied artificial intelligence; the Public Investment Fund is building the national platform layer directly; and the Qatar Investment Authority backs connected-device and digital-health manufacturers. The sovereign funds are therefore simultaneously the largest potential partner, the route to the public rails and the most consequential acquirer in the market, which makes alignment with the sovereign agenda a commercial question rather than a political one.
The capital is also unevenly distributed within the region. Saudi Arabia took roughly 64 per cent of MENA startup capital in the first half of 2025. It led the third quarter with about US$3.2 billion across 62 deals, ahead of the UAE at about US$1.2 billion (MENA funding trackers, 2025). The money has concentrated where the population and the platforms are. That is the same two-market concentration which governs every other variable in this read.
The single regulatory fact that most entrenches the scale problem is the rule that health data must stay home.
The regulatory feature that hardens the scale wall most directly is data localisation. Each Gulf state requires health data to stay within its borders. The UAE’s health-sector ICT law mandates that health data remain in-country, free zones included. Saudi Arabia’s data-governance regime and personal-data-protection law impose their own residency and
transfer controls. The others follow suit. Health data, unlike most goods, cannot move freely across the borders between the six markets.
The consequence is structural and decisive. A digital-health platform’s value comes from aggregating patients and their data. Data localisation means that aggregation cannot happen across the region, so no single platform can legally pool the six markets into one. A company serving Saudi Arabia cannot simply extend the same system, on the same data, into the UAE. It has to build and store separately in each, multiplying cost and fragmenting the very user base it set out to consolidate. The localisation rules are not an oversight. They reflect real sovereignty and security concerns, but their effect on digital health is to turn six small markets into six sealed ones, foreclosing the regional scale that might have offset small national populations. Of all the constraints in this read, data localisation is the one that turns fragmentation from a friction into a wall.
Enforcement, not drafting, is what has changed. The kingdom's Personal Data Protection Law came into full effect on 14 September 2024 and is enforced by the Saudi Data and Artificial Intelligence Authority, which classifies health data at its most restricted tier alongside genetic and biometric data. By mid-January 2026 the authority's committees had issued 48 decisions confirming breaches, most for processing without a lawful basis, unauthorised disclosure or absent safeguards, and a controller has as few as five days to respond once notified (SDAIA, 2026). Localisation in the Gulf is no longer a paper obligation.
The obligations are also deepening in scope. Law-firm commentary from the second quarter of 2026 reports that the authority has moved to sector audits including healthcare. It also reports an expectation of a data-protection impact assessment before health data is processed, together with a registered data-protection officer where processing is large-scale or sensitive. These points rest on secondary sources and warrant verification against the authority's own publications. Even so, the direction is consistent with the enforcement record.
The architectural consequence is the one that bears on scale. A platform serving the region must architect for localisation from the outset. Data is hosted and governed separately under each of the three Gulf health-data regimes rather than consolidated. That forecloses the single regional data pool from which a platform's value would otherwise compound. The cost is incurred per market and recovered against a small population, which is the mechanism by which fragmentation turns a modest market into several marginal ones.
That clarity is a real asset most emerging markets lack. Where Indian e-pharmacy has run for years in a legal vacuum, Gulf telehealth has explicit licensing and defined standards. More decisively, it has reimbursement. A provider knows it can operate legally and get paid. The catch, again, is the border. Each of these supportive regimes is national, so a provider must obtain separate licences in each state, and the certainty it enjoys at home does not extend across the region. The Gulf has built the legal
infrastructure for digital health to thrive within each market (clear rules, a paying payer, defined standards) while leaving the borders between markets as hard as ever. It is the best regulatory environment in the emerging world to operate a digital-health business in, and one of the hardest to scale one across.
Where the data rules fragment, the telehealth rules support: giving the Gulf the legal certainty most markets lack.
If data localisation is the regulatory constraint, telehealth licensing and reimbursement is the regulatory advantage, and the two together capture the Gulf’s regulatory character: supportive within each state, fragmented across them. The Gulf states have built clear, modern telehealth regimes. Dubai issues telehealth standards and licenses well over a hundred providers; Abu Dhabi licenses and reimburses telemedicine at a set fee; Saudi Arabia runs a national telemedicine regulation and a dedicated unit of excellence. Software-as-a-medical-device and even AI medical devices have specific, binding guidance, especially in Saudi Arabia.
The clearest evidence that Gulf regulation supports rather than obstructs is the e-pharmacy segment, where the contrast with India is exact. The Saudi Food and Drug Authority introduced mandatory licensing and
prescription controls for online pharmacies in 2023, so the segment is regulated rather than operating in a vacuum. It has grown accordingly. GCC e-pharmacy is put at about US$2.37 billion in 2024, rising to about US$9.44 billion by 2033 at about 15.4 per cent. It is the most-used digital-health solution in both Saudi Arabia and the UAE (IMARC and McKinsey, 2024 to 2026). Measured retention across digital-health app categories in the two markets runs between 64 and 87 per cent.
Getting paid is likewise defined rather than negotiated. Dubai's eClaimLink, reinforced by directive PD-05-2025, requires electronic claims submission under set timelines with penalties attached, which converts reimbursement from a commercial negotiation into a technical integration. A provider that connects correctly is paid; one that does not is penalised.
The licensing regimes remain national, however, and in the UAE conditional. Telehealth is licensed state by state under published practice rules. In the UAE a licence is contingent on integration with the relevant health-information exchange. Legal certainty is acquired per market rather than per region. The Gulf is therefore among the best regulated markets in the emerging world in which to operate a digital-health business, and among the most expensive in which to assemble one across borders.
AI escapes the population cap that holds consumer health-tech down. A clinical model trained on Gulf compute can serve a small national population superbly and, in principle, be exported far beyond the region, clearing the scale ceiling entirely. AI also attacks the Gulf’s real demand-side
constraint. That constraint is not a shortage of patients but a shortage of clinicians, which AI multiplies. And it plays to the Gulf’s strengths of capital and compute, to its data and to the sovereign authority to deploy nationally, rather than to its weakness in scale. The Gulf may never grow a consumer health-tech champion the size of an Indian or American one, but it can plausibly lead the world in sovereign clinical AI. That is the layer where the number of users matters least, and it is where the everything-but-scale problem is finally solved.
There is one layer of digital health where scale of users matters less than scale of compute, and there, the Gulf leads.
The one part of digital health where the Gulf’s advantages line up perfectly with the opportunity is artificial intelligence. AI runs on scale of compute and capital, which the Gulf has in abundance, rather than scale of users, which it lacks. The region is building genuine AI leadership in health. Abu Dhabi’s M42 trained its Med42 clinical large language model on sovereign supercomputers, reporting performance competitive with the strongest general models on medical benchmarks. Saudi Arabia’s Seha Virtual Hospital deploys AI for imaging pre-reads, breast-cancer and diabetic-retinopathy screening, and has validated smartphone-based
vital-signs reading. The national data-and-AI authority has earmarked tens of billions for AI, with health a priority.
The case for Gulf leadership in clinical artificial intelligence rests on three inputs the region holds. The first is pooled data. Roughly 1.9 billion records are accessible across the UAE's three exchanges, and the Saudi national platform layer aggregates at kingdom scale. That is the precondition a clinical model requires, and most health systems have not met it. The second is compute and capital, with HUMAIN capitalised at about US$10 billion and sovereign funds of roughly US$5 trillion behind the wider build. The third is governance. The Gulf states have framed artificial-intelligence-in-health rules ahead of the deployment curve rather than behind it.
Deployment is already measurable in the public system. Seha Virtual Hospital operates artificial-intelligence-assisted triage with reported accuracy of up to 95 per cent, alongside remote consultation and specialist support. The applied stacks of M42 and G42 sit behind the Abu Dhabi data landscape (Saudi Ministry of Health and company disclosures, 2026). The venture layer is forming in the same direction, if thinly. Nuxera AI raised a US$2.5 million pre-seed round backed by the Sanabil venture studio.
The constraint on this layer is different in kind from the constraint on the rest of the market. Clinical artificial intelligence is gated by talent, data access, clinical validation and governance rather than by user numbers or manufacturing, which is precisely why the Gulf has chosen it. The moat is data access and validated clinical performance, and both are available to a company that builds with the sovereign rather than around it.
The Gulf’s biggest consumer health platforms are not startups. They are government apps, pushed to whole nations at once.
The largest consumer-facing digital-health platforms in the Gulf are state-built super-apps, and Saudi Arabia’s Sehhaty is the exemplar. Built for the health ministry, Sehhaty passed 31 million users and delivered over 51 million virtual consultations and appointments in 2024. Dozens of services are folded into a single national app, among them appointments and records, prescriptions and virtual visits, and even a Google-powered AI health coach. Its penetration, in a country of 35 million, is a level no private app could reach commercially. It got there because the state deployed it to the whole population.
The super-apps reveal the structural truth of Gulf digital health. The user numbers a venture-backed startup dreams of, tens of millions, are captured not by a startup but by a government platform. The platform is handed to citizens as a public service and paid for from the state budget. That both proves the demand (Saudis clearly want digital health, and use it heavily) and forecloses the private opportunity (a startup cannot compete with a free, mandated national super-app). The sovereign super-app is the scale solution and the private-market problem in one. It proves the Gulf can reach digital-health scale, but only through the state, and in doing so it
occupies the consumer space a private company would otherwise contest. For commercial players, the lesson is to integrate with or build for the super-app, not against it.
The super-app layer is broader than a single application, and its breadth is what forecloses the private consumer position. Saudi Arabia fronts its health system with Sehhaty, Mawid and the 937 service, which between them handle appointments, records and telemedicine for the population. In the UAE the citizen-facing layer is bound to the exchanges with which any telemedicine provider must integrate. These are state-built and state-run, free at the point of use. They are the default channel against which a private service is compared.
The private layer that has grown alongside them is instructive in its proportions. Cura, one of the larger Saudi private virtual-care platforms, reports more than 350,000 users and more than 4,500 doctors. Altibbi, the leading health application in the wider MENA region, has raised about US$50 million including a US$44 million Series B in 2023 (company disclosures, 2023 to 2026). These are respectable businesses measured against their capital. They are small measured against a national application distributed by mandate.
The instruction that follows is positional, not competitive. A private operator should specialise, taking a speciality or a population the public service does not serve well, integrate with the public rails for distribution and interoperability, and monetise through the insurer rather than the consumer. The public platforms lower the cost of distribution and of trust for anyone willing to build on them, and they raise it to a prohibitive level for anyone intending to replace them. The super-apps are better read as infrastructure to be used than as competitors to be displaced.
M42 matters because it shows the Gulf playing to its strengths rather than fighting its constraints. It does not try to win a consumer-scale race it cannot win. It builds at the AI and enterprise layer, where the Gulf’s capital,
compute and data lead, and it expands internationally to escape the domestic scale ceiling. Med42 can serve the UAE’s small population and, as an exportable model, reach far beyond it. That is the one path that transcends the 61-million wall. M42 is proof the Gulf can build a digital-health asset of genuine international standing, provided it builds the kind that scales by compute and export rather than by domestic users. It is the everything-but-scale thesis turned into a strategy: lead in AI, expand abroad, and let the sovereign capital do what user numbers cannot.
The Gulf’s most credible claim to digital-health leadership is a sovereign-backed fusion of healthcare and frontier AI.
M42 is the Gulf’s flagship digital-health champion, and it embodies the read’s resolution: build where capital and compute matter more than user scale. Formed in 2023 from the merger of G42 Healthcare and Mubadala Health, M42 employs more than 20,000 people and runs over 450 facilities across 26 countries, international already, because the Gulf market alone is too small to hold its ambition. Its distinctive asset is Med42, an open clinical large language model trained on G42’s sovereign
supercomputers, which M42 reports performs competitively with the strongest general-purpose models on medical examinations.
M42's significance is structural as much as clinical. Mubadala and G42 created the company expressly to fuse care delivery with applied artificial intelligence, which places a single sovereign-backed entity on both sides of the relationship that normally separates a health system from its technology supplier. The same entity also sits on the data layer: Malaffi, the Abu Dhabi health-information exchange, is operated through M42 and Abu Dhabi Health Data Services (company and authority disclosures, 2026). Delivery, data and model development are held within one sovereign-backed group.
That integration is the source of the advantage. The moat in clinical artificial intelligence is data access and validated clinical performance rather than user scale, and an entity that operates the exchange, the hospitals and the model development has privileged access to both. No
independently financed company in a market of this size could assemble the same position, which is why the Gulf's credible claim to leadership in this layer is a sovereign claim rather than a venture one.
The limitation is the counterpart of the advantage. A champion assembled this way is not a template a private operator can follow; it is a counterparty a private operator must plan around. For most commercial players the realistic relationship with M42 and its peers is as a supplier, an integration partner or an acquisition candidate, the sovereign funds being the most consequential acquirers in the market. The strategy the chapter describes is available in full only to those the sovereign builds.
The region’s largest health group solved the scale problem the only way the Gulf can: by buying it overseas.
PureHealth, the Middle East’s largest healthcare group, offers the second route past the scale ceiling. The route is to buy it abroad. Backed by Abu Dhabi’s ADQ, PureHealth raised about $986 million in its December 2023 IPO and posted FY2024 revenue of around AED 25.8 billion, up 58%, net profit up 78%. It grew not by saturating the small Gulf market but by buying internationally. The UK’s Circle Health was acquired
for about $1.2 billion, along with a majority of a major Greek hospital group. The result is a multinational platform across provision, diagnostics, insurance and digital health.
PureHealth confirms the thesis from the commercial side. A Gulf health champion cannot reach world scale within the Gulf, so the successful ones reach outward. M42 runs across 26 countries, and PureHealth has gone into Britain and Greece and holds a US footprint. The domestic market supplies the sovereign capital and the home base. The scale comes from abroad. For an investor, this is the defining pattern of Gulf health platforms. They are sovereign-funded vehicles that use Gulf capital to acquire international scale, not organically-grown businesses scaling a domestic market. PureHealth demonstrates what Gulf capital can build. It also admits quietly what it cannot build at home, which is scale. The growth is real. It just happens overseas, because that is where the people are.
The pattern PureHealth illustrates runs through the region's deal flow more broadly, and it is not confined to outbound acquisition. Much of the largest activity in Gulf health is strategic or sovereign-linked rather than classic early-stage venture. The biggest transactions are structured to buy distribution and installed base rather than to build it. Aster DM's myAster joint venture with Al Hokair, capitalised at about US$250 million to open 186 pharmacies across Saudi Arabia, is the inbound version of the same logic. Scale is acquired through a partner's footprint rather than grown through customer acquisition (company disclosures, 2025 to 2026).
The reason the logic recurs is the arithmetic of the domestic market. Where the addressable population in any one state is small and acquisition cost is high, the cheapest route to a large user base is to purchase one that already exists, whether abroad or through a local incumbent's footprint. Organic consumer growth is the most expensive path available in this market and the least likely to reach venture-scale returns.
For an investor the implication is a test rather than a preference. A Gulf health platform's growth should be examined for its source. The source may be aggregation across the six states, acquisition of an existing footprint at home, or acquisition abroad. Only the first is genuinely regional, and only the first compounds with the market's own growth. Scale bought overseas diversifies the business away from the Gulf constraint rather than solving it.
For all the wealth and ambition, the Gulf’s private health-tech startup scene is strikingly thin, and stale.
The most telling evidence for the scale thesis is what is missing. There is no thriving private health-tech startup ecosystem. For all the payer advantage, the capital and the demand, the Gulf has produced relatively few scaled private digital-health companies, and the landmark funding
rounds are conspicuously dated. The region’s best-known telemedicine startup raised its major round in 2022. Other prominent names in booking and diagnostics, and in insurance technology, raised their last major rounds between 2020 and 2022, and a sweep for fresh 2024–2026 rounds turned up little. The private layer exists, but it is thin and quiet.
The reason is the scale ceiling working exactly as the thesis predicts. A health-tech startup needs a large addressable market to justify venture investment and grow into a valuable company; the Gulf offers a small one, fragmented across six states, with the most attractive consumer space already occupied by free government super-apps. So private founders struggle to build the user base that pulls in follow-on capital, and investors struggle to see the exits that justify the risk. The startups that do succeed tend to serve enterprise or insurer customers (where the payer pays) or to expand abroad early. The thin, stale startup layer is not a failure of talent or capital; it is the predictable consequence of a market that has everything except the scale a startup needs. It is the thesis, visible in an absence.
The thinness is measurable, and recently so. Disclosed GCC health-technology investment amounted to about US$148 million across 32 startups between January 2025 and July 2026, with 21 rounds completed in 2025 and 11 in the first half of 2026. Saudi Arabia accounted for 17 of the companies and the UAE for 11 (PitchBook, via WHX Tech, 2026). This is a narrower scope than the MENA totals usually quoted. It is the figure that corresponds to the question being asked here.
The individual rounds show where the few successes sit. Altibbi has raised about US$50 million including a US$44 million Series B in 2023. It is the region's clearest candidate to reach unicorn standing, precisely because it aggregates demand across several markets. Vezeeta has raised more than US$63 million, moving from booking into teleconsultation and pharmacy software. Klaim raised a US$26 million Series A in 2025 on the claims rail. Okadoc has raised about US$22.3 million and is extending from the UAE into Saudi Arabia. Alma Health raised a US$10 million Series A in virtual chronic care. MedIQ's US$6 million Series A ranks among the largest Saudi health-technology rounds to date.
The composition of that list is the argument. The better-funded companies are regional aggregators, claims and insurer plays, or chronic-care
businesses with a reimbursing payer behind them. The institutional scaffolding is maturing in the same direction, through Hub71+ Life Sciences in Abu Dhabi and the Sanabil venture studio in Saudi Arabia, but it is building a specialist layer rather than a consumer one.
One pair of numbers captures the entire read: billions for sovereign compute, tens of millions for health-tech startups.
If a single comparison proves the everything-but-scale thesis, it is the funding gap. In 2025 the entire GCC health-tech venture market raised about $36.2 million across a dozen rounds. That was a real year-on-year increase, but a tiny figure in absolute terms, against a cumulative all-time total of only some $341 million across 125 companies. In the same window, the Gulf’s sovereign funds were committing billions to AI compute and health platforms. The region deploys billions through the state. It raises tens of millions through venture capital.
The gap is not a contradiction. It is the structure of the market. Venture capital flows to where scale promises returns, and the Gulf’s small, fragmented populations cap the scale a startup can reach. So private health-tech funding stays small, while sovereign capital, which needs no venture-scale user economics, flows freely into state-built platforms and
compute. (One caution on the numbers: much-quoted MENA health-tech totals of hundreds of millions, or all-sector totals in the billions, are wider geographies and often debt-skewed; the clean GCC-only health-tech venture figure is the $36 million.) The funding gap is the read in a single statistic. It is a market awash in sovereign capital and starved of venture capital, because the first does not need scale and the second cannot find it. Money is not the Gulf’s digital-health problem. The absence of the scale that would attract private money is.
The gap is wider still once the sovereign side is quantified on a comparable basis. Disclosed GCC health-technology venture investment was about US$148 million across 32 startups between January 2025 and July 2026. Against that sits HUMAIN, a single Saudi artificial-intelligence venture vehicle, capitalised at about US$10 billion, and sovereign funds holding roughly US$5 trillion in aggregate (PitchBook via WHX Tech, and sovereign-fund disclosures, 2026). A single strategic health transaction, Aster DM's US$250 million pharmacy joint venture, exceeds the region's entire disclosed health-technology venture flow over eighteen months.
The comparison must be made on a stated scope, because the commonly quoted totals are not comparable. MENA startups across all sectors raised about US$2.1 billion in the first half of 2025, up about 134 per cent year on year, of which Saudi Arabia took roughly 64 per cent. Those figures cover every sector and a wider geography than the Gulf, and they are routinely mistaken for health-technology funding. The clean GCC
health-technology series is the US$148 million figure, and it is the only one that answers the question.
The structural reading stands unchanged by the revision. Venture capital is absent not because the Gulf lacks money but because the scale that
produces venture returns is not available domestically. Sovereign capital is appraised against national objectives rather than against user economics, and it flows freely into platforms, compute and strategic acquisition. The two numbers are not in tension. They are the same constraint observed from two sides.
When the state builds the platforms and funds the ventures, what room is left for a private company?
A sharper version of the scale problem is the crowding-out question. Does the sovereign model leave room for a private digital-health sector at all? The dynamic is real, and increasingly noted. The state builds the dominant consumer platforms (the super-apps) and owns the most valuable assets (the virtual hospital, the records). Through the sovereign funds it even incubates ventures directly. That has given rise to what analysts have called the “GCC sovereign startup,” a company founded and funded by a state investor rather than independent venture capital. In a
market this small, a private founder competes against the scale ceiling and against the state itself.
The honest read holds two truths in tension. The sovereign model is genuinely effective. It has built national platforms of the first rank and AI capability that no private market this size could have produced, and it channels patient capital into long-term infrastructure. It also narrows the private opportunity, because the consumer space is occupied, the best assets are state-owned, and independent venture capital is scarce partly because the state is both competitor and the main source of capital. The likely equilibrium is a market where the sovereign builds the platforms and the AI, and private players find their room at the edges, serving enterprise and insurer customers, supplying the sovereign platforms, or expanding abroad. The crowding-out question has no tragic answer, but it has a defining one. In the Gulf, the private digital-health opportunity is shaped, and bounded, by the sovereign that dominates the space.
The crowding-out dynamic can be specified rather than merely asserted, and it operates through three channels. The first is the product channel. Basic virtual consultation is supplied free at national scale by the public platform, so the most accessible consumer proposition is occupied before an entrant arrives. The second is the data channel. The exchanges are state-run and integration with them is mandatory, so the pooled data on which a platform's analytics would compound is held by the sovereign rather than by the company. The third is the capital channel, where the
sovereign funds are at once the largest investor, the route to the rails and the most consequential acquirer.
The third channel is the one that most changes the character of the private layer. Where a venture is founded inside a sovereign programme, as with Nuxera AI's pre-seed round backed by the Sanabil venture studio, the distinction between a startup and a state initiative becomes a matter of structure rather than of substance. Independent capital is scarce partly because the state is both the competitor and the principal source of funds.
The equilibrium this produces is workable rather than closed, and the standing mitigations are known. An operator specialises instead of competing on breadth, and integrates with the public platforms instead of against them. It diversifies channel across the insurer, the employer and the hospital, so that no single programme's timetable governs its revenue. It also partners with sovereign and academic institutions on the talent it cannot otherwise recruit. The private opportunity in Gulf digital health is genuine, and it is defined by the sovereign rather than by the market.
Saudi Arabia’s advantage is that its larger population makes the sovereign-platform model most viable. A national super-app with 31 million users is meaningful scale even by global standards. Its strategy is the most ambitious and best-resourced in the Gulf, pairing the platform build with the sovereign-compute investments (HUMAIN and its AI partnerships) that aim to lead in clinical AI. The limitation is the one the whole read describes. Even 35 million is modest globally, the private startup layer stays
thin beneath the state platforms, and the kingdom’s digital-health value concentrates in government-owned assets. Saudi Arabia is where the sovereign model works best, precisely because it is where the Gulf comes closest to scale, and it is still a market the state, not the private sector, dominates.
The largest Gulf market is also the most fully realised expression of the sovereign-platform model.
Saudi Arabia is the Gulf’s largest digital-health market and the purest case of the platform state. With 35 million people, more than half the region’s population, it has the closest thing the Gulf offers to genuine national scale. It has used the state to build platforms across the whole stack. Seha Virtual Hospital sits at the clinical layer and Sehhaty at the consumer layer, with the PIF-owned platform companies running records and exchanges and the data-and-AI authority funding clinical AI. Vision 2030’s health transformation, the privatisation of hospitals into the Health Holding Company, and a national insurance programme targeted for 2026 complete a coordinated, state-driven build.
Two corrections sharpen the kingdom's position, and both strengthen it. The first is the payer. Saudi Arabia already requires Council of Health
Insurance-compliant cover from every private employer, so the mandate is operative rather than, as stated here, a programme targeted for 2026. The second is the market basis. Saudi digital health is put at about US$4.4 billion in 2025, rising to about US$18 billion by 2032 at about 22 per cent a year. That makes the kingdom roughly seven tenths of the regional market on the re-based GCC total of about US$6.28 billion for the same year (Market Research Future and national series, 2026).
That concentration extends to capital as well as to demand. Saudi Arabia took roughly 64 per cent of MENA startup capital in the first half of 2025 and led the third quarter with about US$3.2 billion across 62 deals. Saudi companies made up 17 of the 32 GCC health-technology companies funded between January 2025 and July 2026. HUMAIN, the Public Investment
Fund's artificial-intelligence venture vehicle capitalised at about US$10 billion, sits behind the compute layer, while the Sanabil venture studio supplies the thin venture layer above it.
The kingdom is therefore the only Gulf market in which the sovereign model operates at something approaching genuine national scale, and it is also the market in which the state's share of the available value is highest. The clinical layer, the citizen front-ends, the records and the compute are all state-held. A private operator's position in Saudi Arabia is accordingly defined by what it can supply to that landscape, or by the specialities and populations the state serves least well.
The UAE’s bet is that connectivity, capital, regulatory sophistication and openness can make it the place where Gulf digital health is funded, built
and exported, even with a small population at home. It leads the region in health-information exchange, in AI, and in attracting and deploying sovereign and foreign capital. The strategy is honest about the ceiling. Rather than pretend 11 million is a large market, it aims to be the node through which the region’s digital-health capital and capability flow outward. The limitation is that a hub strategy leans on the AI and enterprise layers, where the UAE genuinely leads, not on consumer scale, which it lacks as much as anyone. The UAE has chosen the smartest available answer to everything-but-scale. The ceiling is not fought but built above, in AI, in capital, in international reach.
Too small to scale at home, the UAE built the model that escapes the ceiling: become the regional and AI hub.
The UAE, with about 11 million people, cannot chase scale through its domestic population, so it has built the Gulf’s most deliberate strategy for transcending the ceiling: become the hub. Abu Dhabi’s health groups, M42, PureHealth and the wider G42-and-Mubadala constellation, are explicitly international, expanding across dozens of countries and acquiring abroad. The emirate has cast itself as the regional centre for health AI (Med42, sovereign compute, the Stargate campus), for health data and
research (Malaffi, the life-sciences clusters), and for the regional headquarters and operations of global firms.
The hub strategy is visible in the figures, and the figures require care. UAE digital health is put at about US$0.93 billion in 2025, rising to about US$7.6 billion by 2035 at about 23 per cent a year. That is the fastest headline rate in the region, achieved from a base roughly one fifth the size of Saudi Arabia's (Market Research Future and national series, 2026). A high growth rate on a small base is not the same thing as scale. The UAE's strategy is constructed on precisely that recognition.
The emirates' genuine lead is in the data layer. Three interconnected exchanges, Malaffi in Abu Dhabi, NABIDH in Dubai and Riayati nationally, make roughly 1.9 billion records accessible. NABIDH alone holds about 10.4 million records across 1,888 facilities, and Riayati connects about 5,000. Integration is mandatory for telemedicine providers. No other Gulf state has assembled an equivalent data layer, and it is the substrate on which clinical artificial intelligence is built.
The payer position is equally advanced. Compulsory cover for private-sector workers and uncovered domestic employees took effect on 1 January 2025. Health premiums rose about 12.7 per cent in the first half of that year, and Dubai's eClaimLink, reinforced by directive PD-05-2025, enforces electronic claims under defined timelines. Against that, capital flow remains secondary to Saudi Arabia's. The UAE recorded about US$1.2 billion of startup funding in the third quarter of 2025 against the kingdom's
US$3.2 billion, and 11 of the 32 funded GCC health-technology companies to July 2026. The UAE leads on data, regulation and the payer rail, and follows on scale and capital.
For the four small states, scale is not a challenge to overcome but a fact to design around.
Qatar, Kuwait, Oman and Bahrain meet the scale problem in its most acute form. Populations run from 1.6 to 5 million, too small to anchor any consumer health-tech business or to justify the venture
economics of a private platform. Their response is necessarily different from Saudi Arabia’s platform-state or the UAE’s hub. They build national digital-health infrastructure for their own citizens and largely import or buy the technology to do it. Qatar runs its national record on a global electronic-health-record system and, backed by the Qatar Investment Authority’s vast resources, invests in high-value specialised medicine. Kuwait launched a consolidated national health app in late 2025. Oman and Bahrain run national systems of their own.
| State | Population (2024) | Digital-health system |
|---|---|---|
| Qatar | ~3.2M | National record (global EHR); QIA-funded specialist medicine |
| Kuwait | ~5.0M | “Salem” national app (2025) |
| Oman | ~5.3M | Al-Shifa national EHR |
| Bahrain | ~1.6M | I-SEHA national system |
For these states the strategic reality is that domestic scale is simply unavailable. The sovereign-platform model is therefore the only one that works. A national system is built for a small population and funded from the state, and no private market is expected to emerge at that size. Their leverage, where they have it, lies in wealth per capita (Qatar can buy frontier capability for a small, rich population) and in the possibility of pooling with their neighbours, which the fragmentation and data walls currently prevent. The smaller states are the scale problem in its purest form. They
are markets too small for private digital health, served well by the sovereign, and dependent on the state precisely because no other model works at their size. They are the clearest illustration of why, in the Gulf, the answer to digital health is the government, because for four of the six states, there is no alternative.
The four smaller states differ from one another more than their size suggests, and the differences determine the order in which they should be approached. Bahrain is the agile, finance-led market and the cleanest regulatory proving ground. Its SEHATI scheme, established under Law 23 of 2018, carries an allocation of BD 688 million and covers roughly 686,000 expatriate residents and their dependants. The scheme remains in phased rollout rather than fully in force. Oman is earlier-stage and public-led, running the Al Shifa national electronic medical record, with its Dhamani insurance platform launched on 1 January 2025 and likewise still phasing in.
Qatar is the premium, research-led market, running its national record on an enterprise system at Sidra Medicine, supported by Qatar Investment Authority capital and a genomics programme. It also carries the region's second-heaviest diabetes burden, at about 24.6 per cent of adults (International Diabetes Federation, 11th edition, 2025). Kuwait is demand-rich and reform-slow, with the highest prevalence in the region at about 25.6 per cent and the Dasman institute as its research anchor.
The strategic reading is that these are payer-and-data-gated opportunities to be approached individually rather than a residual block. Qatar buys
frontier capability for a small, wealthy population. Kuwait's disease burden underwrites chronic-care demand that its reform pace has yet to meet. Bahrain's agility makes it a sensible first market for a regulated pilot. Oman's Dhamani rollout is the development worth watching, because it is the clearest near-term test of whether the payer mandate extends beyond the two large markets.
The deal flow confirms the structure: sovereign money building platforms and buying scale abroad, not funding domestic startups.
The transactions of recent years map the read’s structure precisely. The largest deals are sovereign and international. Microsoft put $1.5 billion into G42, and HUMAIN and the UAE’s AI campuses carry multi-billion-dollar AI-compute partnerships. PureHealth’s near-billion-dollar IPO was followed by its $1.2 billion acquisition of a UK hospital group, and M42 was formed and expanded internationally. The money is vast and patient, it is sovereign, and it is pointed at platforms, compute and overseas acquisition rather than at domestic consumer health-tech startups, which raise the tens of millions documented earlier.
Capital allocation follows the thesis exactly. Where scale promises returns, in exportable AI, in international acquisitions, in national infrastructure the
state will fund regardless, the money flows freely. Where scale is capped, in domestic consumer health-tech, private capital stays away, and the gap is filled, if at all, by the sovereign incubating ventures itself. For an investor, the implication is to follow the sovereign and the export path. The value is in the state-built platforms, in the AI champions that scale by compute and reach abroad, and in the international acquisitions that buy the scale the region lacks at home. It is not in domestic consumer plays fighting free government super-apps for a small population. The deals do not contradict the thesis. They execute it. Capital goes where scale is, and in Gulf digital health, scale is found in AI, in the sovereign, and abroad.
The deal record is worth citing in its own terms. The defining transactions of the period are strategic or sovereign-linked rather than classic early-stage venture. HUMAIN was formed as a Public Investment Fund artificial-intelligence vehicle capitalised at about US$10 billion. M42 was created by Mubadala and G42 to combine care delivery with applied artificial intelligence. Aster DM's US$250 million myAster pharmacy joint venture with Al Hokair covers 186 pharmacies across Saudi Arabia, and Klaim's US$26 million Series A in 2025 ran on the claims rail (company and sovereign-fund disclosures, 2025 to 2026).
The geographic distribution of that flow is as concentrated as the market itself. Saudi Arabia took roughly 64 per cent of MENA startup capital in the first half of 2025, and about US$3.2 billion across 62 deals in the third quarter, against the UAE's US$1.2 billion. The whole of disclosed GCC
health-technology venture investment amounted to about US$148 million across 32 startups in the eighteen months to July 2026.
The route to scale is therefore institutional rather than competitive, and this is the practical conclusion for a founder or an investor. Alignment with the sovereign and strategic agenda is the more reliable path. That means the public rails, the insurer relationships, partnership and eventual acquisition. The alternative is an independent venture pipeline that the region's capital markets do not yet support at health-technology scale. The deals are not evidence of a thriving private market. They are evidence of a sovereign market with a private periphery.
The 2026 results confirm where the returns are actually being earned. PureHealth lifted group revenue nine per cent to 14.9 billion dirhams in the first half of 2026, with earnings before interest, tax, depreciation and amortisation up 24 per cent to 2.9 billion dirhams (PureHealth, 2026). International revenue rose 56 per cent to 5.0 billion dirhams on the consolidation of Hellenic Healthcare Group in Greece and Cyprus, and overseas
operations supplied a third of group revenue. Growth abroad outran growth at home. By the nine-month mark net profit stood at 1.8 billion dirhams, higher by 14.1 per cent on the year.
Beneath the sovereign tier, the private rounds of 2026 stayed small and largely strategic. TruDoc, which runs virtual-first primary care and a hospital-at-home programme in the Emirates and Saudi Arabia, raised 15 million dollars in a pre-Series B led by the Al Nahyan and Al-Ketbi families in March of that year (TruDoc, 2026). Hakeem Health followed in May with 1.65 million dollars for clinical decision support, led by Merak Capital with Sanabil 500 participating. Sovereign-linked funds set the terms. Against the sovereign cheques these are rounding errors.
Two features of the 2026 record bear directly on strategy. The first is that the insurer rail now carries earnings of its own, Daman having written gross premium of 5.5 billion dirhams in the first half, up 13 per cent, across an insured membership of 3.4 million (PureHealth, 2026). The second is that acquisition remains the preferred instrument at home as well as abroad, six facilities being bought from Aspen Clinics in Abu Dhabi and Al Ain in November 2026. Capability is purchased rather than incubated. A founder should price that in from the outset.
The Gulf can buy almost anything for its health system. The one thing it cannot purchase is the size of its own population.
The deepest conclusion of this read is that scale is the one input sovereign capital cannot buy. The Gulf has shown that money can purchase first-rate platforms, the largest virtual hospital on earth, frontier AI compute, international hospital groups, the regional headquarters of every global health firm. It can fund universal coverage, mandate insurance, and push a super-app to 31 million citizens. There is almost nothing in health that Gulf capital cannot acquire. The exceptions are a larger population and a unified market.
That is why the scale constraint is so fundamental and so resistant. A payer can be legislated; capital can be deployed; platforms can be built; talent can be imported. But the number of people in the six states, and the borders that divide them, are facts capital cannot change. The Gulf can buy scale abroad, PureHealth in Britain, M42 across 26 countries. It can also transcend scale through AI that exports beyond the region. What it cannot do is conjure a domestic mass market where the demography does not provide one. The everything-but-scale condition is not a phase the Gulf will spend its way out of. It is a structural feature of a wealthy and small region, and a fragmented one. The strategic response is not to wait
for scale to arrive but to build where scale matters least, the sovereign platform, the AI layer, the international expansion. The one thing the Gulf’s wealth cannot manufacture is domestic consumer scale.
The re-based market series makes the point more forcefully than the original did. On the superseded basis, compounding at about 21 per cent a year, the Gulf would have grown its way towards a substantial market within a decade. On the current basis the region is put at about US$23.8 billion by 2035, growing at about 14.2 per cent from about US$6.28 billion in 2025 (Market Research Future, 2026). Growth above 20 per cent survives only in Saudi Arabia and the UAE taken separately. The revision matters because it removes the one answer to the scale problem that required no strategy. That answer was waiting.
Scale is not the only unbuyable input. Clinical and engineering talent in the Gulf is scarce, contested and largely imported, and it cannot be legislated into existence any more than population can. The standing mitigation is partnership with sovereign and academic institutions alongside deliberate importation and training, which is a programme measured in years rather than a transaction measured in months. A region that can commission a
virtual hospital connecting 241 hospitals and more than 1,400 health centres cannot commission the clinicians to staff the system behind it.
What capital does buy, it buys outright, and the distinction is worth holding. It buys platforms and compute, pooled records and regulatory capacity, and foreign hospital groups. It does not buy population. It does not dissolve the three health-data regimes that divide the region, and it does not shorten the time required to train a workforce. The strategic response is to build where those three absences do not bind, which is the sovereign platform, the artificial-intelligence layer and the insurer rail.
A blunt strategic simplification cuts through the fragmentation: in practice, the Gulf is two markets, not six.
For all the talk of six states, the practical reality for a digital-health player is that the Gulf is two markets that matter and four that mostly do not. Saudi Arabia and the UAE together hold the great majority of the region’s population. They hold an even larger share of its health spending, around 83%, and effectively all of its scale, capital, platforms and AI capability. Qatar, Kuwait, Oman and Bahrain are small. They are well-served by their own sovereign systems, and individually too minor to anchor a
regional strategy. The honest strategic map of Gulf digital health has two anchors and four footnotes.
The simplification clarifies the opportunity and the limit. The opportunity is that a player serious about the Gulf can concentrate on two markets, the Saudi platform state and the UAE hub, and capture most of the available value without the cost of six separate market entries. The limit is that even those two, combined, are about 47 million people across two separate regulatory and data regimes. That is meaningful, but still a fraction of one large emerging market, and still divided. The two-of-six framing does not solve the scale problem (two small markets are not one large one) but it focuses it. The Gulf digital-health opportunity is, in practice, a Saudi-and-UAE opportunity, pursued through the sovereign and the AI layer. It is best understood as two rich, capped markets rather than one region of six. For most players, the smaller four are not where the strategy lives.
The two-market concentration can be stated on the market's own figures rather than on the health-spending proxy, and the result is firmer. Saudi digital health is put at about US$4.4 billion in 2025 and UAE digital health at about US$0.93 billion, against a re-based regional total of about US$6.28 billion for the same year. The two markets therefore account for roughly 85 per cent of Gulf digital-health spend (Market Research Future and national series, 2026). The remaining four states divide about US$1 billion between them. That is below the threshold at which a dedicated market entry recovers its own compliance cost.
The concentration holds on the capital side as well. Of the 32 GCC health-technology companies that raised disclosed funding between January 2025 and July 2026, 17 were Saudi and 11 were from the UAE, leaving four across the other states combined (PitchBook, via WHX Tech, 2026). Demand, platforms, capital and deal flow concentrate in the same two markets, which is unusual: these variables diverge in most regions.
The simplification is nonetheless a focusing device rather than a solution, and the arithmetic should be kept in view. Two markets of about US$5.3 billion combined, governed by separate regulators and separate health-data regimes, do not constitute one market of that size. The integration and compliance costs are incurred twice, while the growth rates, at about
22 and 23 per cent respectively, apply to two separate bases. The Gulf opportunity is a Saudi-and-UAE opportunity, pursued twice.
These constraints share a character. Like scale, they are structural rather than fixable by a single decision, and several are the price of the very sovereignty that makes the Gulf model work. Data localisation reflects genuine security concerns; expatriate dependence reflects small national populations; fiscal dependence reflects the resource base that funds everything. They are not failures of execution but features of the region’s
situation, which is a small and wealthy cluster of states, resource-dependent and conscious of its sovereignty. They do not negate the Gulf’s genuine advantages, but they bound them, and they explain why the everything-but-scale condition is durable. The Gulf’s digital-health strengths and its constraints flow from the same source. It is rich and small, sovereign and divided.
Scale is the binding constraint, but it does not stand alone: four others compound it.
Scale is the defining constraint, but an honest read names the others that compound it:
Two of the four constraints can be stated more precisely, and a fifth should be added. The fragmentation constraint is a matter of seven health regulators and three separate health-data regimes rather than six of each. The additional regulator arises from the UAE's split of authority between federal and emirate level. The talent constraint is not only a dependence on imported staff but a contest for it. Clinical and engineering talent is scarce across all six states simultaneously, so the states compete with one another and with the private sector for the same pool.
The fifth constraint is dependence on the state's pace. Where distribution, the data layer and increasingly the payer rail are public, a private operator's roadmap is partly determined by a ministry's, and the rails differ by country so the dependency is incurred separately in each. The standing mitigation is diversification of channel rather than of geography: an operator earning revenue from insurers, employers and hospital systems alongside the public platform is less exposed than one whose distribution runs through a single programme.
The character these constraints share is that each is the cost of something the region values. Data localisation is the price of data sovereignty; imported talent is the consequence of small national populations; dependence on the state is the counterpart of receiving distribution and trust as public
infrastructure. None is an execution failure. None is removable by a single decision. The constraints and the advantages in this market are generated by the same facts, which is why the condition this read describes is durable rather than transitional.
For the right kind of player, the Gulf is an exceptional market: provided the strategy fits the scale.
For a digital-health player whose model fits the Gulf’s shape, the region is among the most attractive in the world. There is a paying payer and abundant capital, clear telehealth regulation and acute demand. The viable strategies follow straight from the read. Build for or with the sovereign platforms rather than against them. Supply or power the government super-apps and virtual hospitals, or integrate with them. Serve the enterprise and insurer layer, where the payer pays, rather than chasing consumers against free state apps. Lead with AI, which scales by compute and export, not domestic users. And concentrate on Saudi Arabia and the UAE, the two markets with the scale and capital that matter.
Three risks could bend the trajectory. Fiscal dependence is the deepest: the sovereign spending that funds the platforms and the compute rests on
oil, and a sustained price fall would slow it. The crowding-out dynamic could intensify, the state taking ever more of the space and leaving private players a shrinking edge. And the fragmentation could persist or harden, keeping the markets sealed and capping the regional scale that might one day offset small populations. None of these reverses the Gulf’s structural advantages (the payer, the capital, the demand and the AI lead are real and durable), but each shapes who captures the value, and how. The Gulf is not a market to enter with a consumer-scale playbook; it is a market to enter with a sovereign-and-AI playbook, sized to two rich markets rather than one large one.
The viable channels can be ranked, and the ranking is unambiguous on economics. The insurer and employer channel offers the strongest position. Cover is compulsory, group cover is employer-funded and recurring, and the claims rail is enforced, so revenue is payer-funded and repeating. Public-platform integration follows, supplying low-cost reach and interoperability at the state's pace. The provider and hospital channel is sticky
and integration-led but carries a long sales cycle. Direct-to-consumer is last. It is viable only for premium or speciality propositions or for a platform already aggregated across the region, because acquisition cost is high and the domestic audience in any one state is small.
The entry sequence follows from the market's concentration. Build for Saudi Arabia and the UAE first, where the demand, the platforms and the capital are. Integrate with the public rails and the insurer from the outset rather than retrofitting. And approach Bahrain, Qatar, Kuwait and Oman as separate payer-and-data-gated opportunities, taking Bahrain first for its regulatory agility and watching Oman's Dhamani rollout as the test of whether the mandate spreads.
The risk register is correspondingly specific. Competition from free public platforms is mitigated by specialisation and integration rather than by price. Data sovereignty across three regimes is mitigated by architecting for localisation from the start, which is expensive to retrofit and cheap to design in. Talent scarcity is mitigated through sovereign and academic partnership. Dependence on state pace is mitigated by channel diversification. Each is manageable, and none is avoidable.
What a player or investor should expect Gulf digital health to look like by 2028.
Over the next two to three years Gulf digital health will deepen along the same lines. It will be sovereign-led and AI-forward, and bounded by scale. Four developments are most likely:
The binding question stays scale, and it will not resolve, because demography and borders do not change on a three-year horizon. The Gulf will keep building the best-funded, best-regulated, most AI-advanced
digital-health system in the emerging world. It will keep doing it through the sovereign, for small markets, with private champions reaching abroad for the scale home cannot give. The smart position, for player and investor alike, is to treat the Gulf as what it is. It is a sovereign-and-AI market, exceptionally resourced and structurally capped, where value accrues to whoever builds for the state and the AI layer and looks abroad for scale. It is not a market in which to scale a consumer business.
The growth expectation should be re-based before the forecasts are read. The regional series now compounds at about 14.2 per cent to 2035 rather than the roughly 21 per cent on which this read was first constructed. The decade ahead is therefore slower in aggregate than previously projected. The fastest segments remain well above the regional rate. Telehealth is at about 21.9 per cent to 2033, and the two leading national markets at about 22 and 23 per cent (Market Research Future, IMARC and Precedence Research, 2024 to 2026). Growth in Gulf digital health is now a segment and country story rather than a regional one.
Four developments are worth watching specifically, because each is dated. Oman's Dhamani platform, launched on 1 January 2025, and Bahrain's SEHATI are both still phasing in, so the next two years determine whether the payer mandate extends beyond Saudi Arabia and the UAE. Saudi enforcement of the Personal Data Protection Law is intensifying, with 48 breach decisions issued by mid-January 2026 and sector audits in healthcare reported from the second quarter of that year. That raises the
compliance floor for every operator holding Gulf health data. The public platform layer continues to deepen, Seha having been relaunched in March 2025 on an expanded model. And the venture layer remains thin, at about US$148 million disclosed across 32 companies to July 2026.
The binding question will not resolve on this horizon. Population and borders do not change in three years, and the re-based growth rate removes the prospect of outgrowing them.
What it lacks is scale. There are 61.2 million people across six separately-regulated states, with data-localisation walls blocking a single regional platform and a transient, expatriate-heavy population. That single absence reshapes everything. It caps consumer health-tech economics (GCC health-tech venture funding was about $36 million in 2025), concentrates value in sovereign-built platforms and the AI layer, and pushes the
region’s champions to acquire scale abroad. The Gulf solved the payer and capital problems. It cannot solve the scale problem, because scale is the one input sovereign wealth cannot buy.
The argument, restated with the evidence behind it.
The Gulf has every ingredient digital health needs except one. It has a rich institutional payer, universal state care plus mandatory insurance, with telehealth reimbursed at parity, that solves the unit-economics problem crippling digital health elsewhere. It has bottomless sovereign capital. Its AI compute is among the largest anywhere. It has government-built platforms at national scale, from the world’s largest virtual hospital to national record exchanges. And it has acute demand, driven by one of the heaviest disease burdens on earth and a shortage of clinicians. By every measure that gates digital health in India or Africa, the Gulf is rich.
For the player and the investor, the read is to fit the strategy to the structure. Build for the sovereign platforms and the AI layer. Serve the payer and the enterprise, concentrate on Saudi Arabia and the UAE, and look abroad for the scale the region cannot provide.
Three of the figures on which this read rests have been re-stated. The market basis is now about US$6.28 billion in 2025, reaching about US$23.8 billion by 2035 at about 14.2 per cent a year. That supersedes the roughly US$5.41 billion at about 21 per cent on which the argument was first built, with growth above 20 per cent surviving only in Saudi Arabia and the UAE taken separately (Market Research Future, 2026). The public platform is recorded at 241 hospitals and more than 1,400 health centres (Saudi Ministry of Health, 9 August 2026). And the disease burden has been re-based to the International Diabetes Federation's 11th edition, published in 2025 on 2024 estimates, giving a Gulf range of 18.7 to 25.6 per cent of adults against a global 11.1 per cent.
None of the three weakens the argument, and the first strengthens it. A market compounding at 14 per cent rather than 21 per cent has less prospect of growing past its own constraint, so the scale problem is more binding on the current basis than on the superseded one. The disease burden is heavier and more evenly spread than previously stated, and the platform is wider.
The payer, meanwhile, is arriving unevenly: compulsory in the UAE from 1 January 2025 and required of every Saudi private employer, but still
phasing in through Bahrain's SEHATI and Oman's Dhamani. The read therefore holds in its corrected form. Everything but scale, with the scale constraint tighter, the demand heavier, and the payer advantage concentrated in the same two markets as everything else.
Nine conclusions for the people who must act on this market.
The engineering work the sector asks for, and the form it takes on an engagement.
Digital health in the Gulf is built on national platforms and a state payer, so the engineering it needs is integration, assurance and operations rather than consumer growth. The work below is what providers, payers and platform operators in this market commission. Each is delivered by senior engineers working inside the client's own team, with the Global Delivery Centres running what has been built once it is in production.
Readiness here is a governance question before it is an engineering one. The buyer who knows who owns patient identity, and where consent sits, can scope an integration in weeks, while the one who does not spends a quarter finding out. Ownership of the national interfaces usually sits
with one team and the clinical record with another. That split is where programmes stall. Volge asks for it to be settled in writing at the outset, because engineering cannot close an unassigned decision.
Engagements of this kind are staffed thin at the top and deep in the middle. A principal architect carries the regulatory and integration design, stays accountable for it after go-live, and does not rotate off, because conformance reasoning is not transferable in a handover document. Below sit engineers who hold the national profiles and the runbooks. Governance runs weekly against a single plan. A reporting pack is not a plan.
Conformance here is an evidentiary obligation, not a gate passed once. Integration with a national exchange rests on published profiles of Fast Healthcare Interoperability Resources, and a platform certified against last year's version of them is not certified (Health Level Seven International, 2019). The profiles keep moving. The practical answer is a test harness the client owns, run on every release, so that evidence is producible on request. Volge builds that harness during the first integration rather than after the first audit.
The first ninety days decide whether the rest of a programme is affordable. The opening month establishes where a client actually stands against each regulator, tested in the running systems, not read off a document. The second settles identity and consent, which gate everything downstream, and the third delivers one integration end to end, in production, for a small clinical population. Nothing larger is attempted. A programme that
cannot show a live interface by that quarter's close has a design problem, not a resourcing one.
Measurement should be clinical and operational, not a count of interfaces delivered. The useful numbers are the share of encounters reaching the national record without manual repair, and the time taken to onboard a new facility, both reportable from the first release. Three failures recur. Programmes treat consent as a screen rather than an architecture, and they buy a platform certified in another market assuming the certification travels. Run and operate is left to last, which is where the cost of the first two appears.
The bodies cited in this read for market, funding, disease and regulatory figures, with the year the text attributes to each.
Volge is an engineering firm providing enterprise technology transformation services to clients across the Middle East, India, APAC, Europe, and North America.
Delivery stands on two pillars: Forward Deployed Engineering, with senior specialists embedded in the client’s own team, and Intelligent Command Centre Operations, run from our Global Delivery Centres, which keeps what they build running. Senior engineers stay with an engagement from the first diagnosis through to production.
Our services span Strategy, Data, Platforms, AI and Automation, Cyber Trust, Technology Operations, and Applied Functional Engineering. Engagements begin with a diagnosis. The firm is built on working autonomy: engineers decide, innovate, co-create, and own their work. Motivated engineers build the systems that sustain our clients’ growth.
This edition may be shared with organisations evaluating a Volge engagement. It may not be altered or republished without Volge’s permission, and figures carry their stated basis and date. Volge, Intelligent Command Centre, and Intelligent Command Centre Operations are marks of Volge; other names are the trademarks of their respective owners.